Chapter IV.5. What is the Evidence that a Dementia Treatment Works?

  1. Nawab Qizilbash MBChB, MRCP, MSc, DPhil (Oxon)1,2
  1. Paul Leber,
  2. David Millson,
  3. David Jolley,
  4. Harry Ward,
  5. Nawab Qizilbash and
  6. Lon S. Schneider

Published Online: 14 JAN 2008

DOI: 10.1002/9780470752340.ch30

Evidence-based Dementia Practice

Evidence-based Dementia Practice

How to Cite

Leber, P., Millson, D., Jolley, D., Ward, H., Qizilbash, N. and Schneider, L. S. (2003) What is the Evidence that a Dementia Treatment Works?, in Evidence-based Dementia Practice (ed N. Qizilbash), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470752340.ch30

Editor Information

  1. 1

    Visiting Professor of Geriatric Medicine, Hospital Universitario GM-Cantoblanco, 280049 Madrid, Spain

  2. 2

    Member of Green College, Oxford University, Oxford, UK

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2003

ISBN Information

Print ISBN: 9780632052967

Online ISBN: 9780470752340



  • administration;
  • considerations;
  • medicines;
  • flexibility;
  • antidementia


This chapter contains section titled:

  • The FD & C Act: its aims, provisions and enforcement by the FDA

  • Introduction

  • Regulations and guidelines

  • The decision to develop antidementia guidelines

  • The guidelines development effort

  • Pseudospecific antidementia claims

  • Vetting of the proposed approach

  • Sources of dissatisfaction with the proposed guidelines

  • Looking backwards

  • Looking to the future

  • Conclusions

  • Introduction

  • Background: the UK societal framework for the purchasing and commissioning of drug treatments for AD

  • What are the issues for purchasing an Alzheimer's drug in the USA?

  • Conclusions

  • Introduction

  • Methods

  • Results

  • Discussion

  • Conclusion

  • Introduction

  • Appropriate situations for

  • of-1 trials

  • Inappropriate situations for

  • of-1 trials

  • Is an

  • of-1 trial feasible in dementia?

  • Practical aspects of conducting

  • of-1 trials

  • Is an

  • of-1 trial appropriate for dementia, MCI and age-related cognitive decline?

  • Can I conduct

  • of-1 trials in my practice?

  • Choosing outcomes to assess effects

  • Evaluation of response and stopping rules

  • Ethics